| abstract |
Provided are methods and compositions for treating Dogo's disease. The present disclosure relates to, among other things, compositions containing human complement inhibitors and / or interferon alpha inhibitors, and the use of such compositions in methods for treating or preventing Dogo disease in a subject. In some embodiments, the inhibitor is an antibody or antigen-binding fragment thereof that binds to a human complement component C5 protein, or a biologically active fragment of C5, such as C5a or C5b. In some embodiments, the inhibitor is an antibody or antigen-binding fragment thereof that binds to interferon alpha or an interferon alpha receptor. [Selection figure] None |